The White House traded dueling accusations of unpatriotic behavior with the CEO of a major drugmaker after unexpectedly tough new rules from the U.S. Treasury Department on corporate inversions derailed a $160 billion merger between Pfizer Inc. and Allergan Plc.
Source: Bloomberg Politics